ESTRO 2025 - Abstract Book

S3973

Radiobiology - Tumour radiobiology

ESTRO 2025

Keywords: Pancreatic cancer, SBRT, molecular subtypes

References: S. Martens, P. Lefesvre, R. Nicolle et al. Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. Ann. Oncol. 30 , 1428-1436 (2019) C. Bouchart, J-L. Engelholm, J. Closset et al. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. Ther. Adv. Med. Oncol . 13 , doi:17588359211045860 (2021). E. Michiels, H. Madhloum, S. Van Lint et al. High-resolution and quantitative spatial analysis reveal intra-ductal phenotypic and functional diversification in pancreatic cancer. J Pathol . 262 , 76-89 (2024).

1309

Poster Discussion Measured intrapatient radiomic variability as a predictor of treatment response in multi-metastatic patients Caryn Geady 1 , Shaghayegh Reza 2 , Denise Reinke 3 , Scott Schuetze 3 , Benjamin Haibe-Kains 1 , Andrew Hope 2 1 Medical Biophysics, University of Toronto, Toronto, Canada. 2 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. 3 Internal Medicine, University of Michigan, Ann Arbor, USA Purpose/Objective: This study investigates the relationship between measured intra-patient radiomic variability (MIRV) and treatment response in the metastatic setting. Specifically, we hypothesize that greater differences in radiomic phenotypes between lesions correlate with variability in treatment response, potentially impacting personalized treatment strategies.

Material/Methods:

A retrospective analysis was conducted on 350 multi-metastatic patients from a Phase III trial (TH CR-406/SARC021, NCT01440088; details in [1]) comparing Doxorubicin Monotherapy with Doxorubicin plus Evofosfamide for advanced soft-tissue sarcoma. Radiomic features were extracted [2] from pretreatment imaging for all lesions,